Biomaterial Database

A 16-year-old boy with altered mental status. 2013

Robert Listernick

Northwestern University, Feinberg School of Medicine, Division of Academic General Pediatrics, Chicago, IL, USA.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D009459	Neuroleptic Malignant Syndrome	A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)	Neuroleptic-Induced Neuroleptic Malignant Syndrome,Neuroleptic-Malignant Syndrome, Neuroleptic Induced,NMS (Neuroleptic Malignant Syndrome),NMSs (Neuroleptic Malignant Syndrome),Neuroleptic Induced Neuroleptic Malignant Syndrome,Neuroleptic Malignant Syndrome, Neuroleptic Induced,Neuroleptic Malignant Syndromes,Syndrome, Neuroleptic Malignant,Syndromes, Neuroleptic Malignant
D003693	Delirium	A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)	Delirium of Mixed Origin,Subacute Delirium,Delirium, Subacute,Deliriums, Subacute,Mixed Origin Delirium,Mixed Origin Deliriums,Subacute Deliriums
D003937	Diagnosis, Differential	Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures.	Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001523	Mental Disorders	Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders
D060426	Anti-N-Methyl-D-Aspartate Receptor Encephalitis	Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies.	Anti-NMDA Receptor Encephalitis,Anti-NMDAR Encephalitis,Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis,Non-paraneoplastic Anti-NMDA Receptor Encephalitis,Non-paraneoplastic Anti-NMDAR Encephalitis,Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis,Paraneoplastic Anti-NMDA Receptor Encephalitis,Paraneoplastic Anti-NMDAR Encephalitis,Anti N Methyl D Aspartate Receptor Encephalitis,Anti NMDA Receptor Encephalitis,Anti NMDAR Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitides,Anti-NMDA Receptor Encephalitides,Anti-NMDAR Encephalitides,Anti-NMDAR Encephalitides, Non-paraneoplastic,Anti-NMDAR Encephalitides, Paraneoplastic,Anti-NMDAR Encephalitis, Non-paraneoplastic,Anti-NMDAR Encephalitis, Paraneoplastic,Encephalitides, Anti-N-Methyl-D-Aspartate Receptor,Encephalitides, Anti-NMDA Receptor,Encephalitides, Anti-NMDAR,Encephalitides, Non-paraneoplastic Anti-NMDAR,Encephalitides, Paraneoplastic Anti-NMDAR,Encephalitis, Anti-N-Methyl-D-Aspartate Receptor,Encephalitis, Anti-NMDA Receptor,Encephalitis, Anti-NMDAR,Encephalitis, Non-paraneoplastic Anti-NMDAR,Encephalitis, Paraneoplastic Anti-NMDAR,Non paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis,Non paraneoplastic Anti NMDA Receptor Encephalitis,Non paraneoplastic Anti NMDAR Encephalitis,Non-paraneoplastic Anti-NMDAR Encephalitides,Paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis,Paraneoplastic Anti NMDA Receptor Encephalitis,Paraneoplastic Anti NMDAR Encephalitis,Paraneoplastic Anti-NMDAR Encephalitides,Receptor Encephalitides, Anti-NMDA,Receptor Encephalitis, Anti-NMDA
D017809	Fatal Outcome	Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.	Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal